Department of Pediatrics, Hanchuan People's Hospital, Hanchuan, Hubei, China.
Medicine (Baltimore). 2021 May 21;100(20):e25534. doi: 10.1097/MD.0000000000025534.
Osteosarcoma is a primary form of malignant bone tumor. It is commonly prevalent among children. Treating osteosarcoma with chemotherapy has had limited clinical outcomes due to side effects and the formation of drug resistance. Presently, a mixture of doxorubicin, cisplatin, ifosfamide, epirubicin methrotrexate, and other supplementary medications are used in osteosarcoma chemotherapy. Therefore, this study aims to investigate the clinical therapeutic effects of combining methotrexate with other chemotherapeutic agents to treat osteosarcoma in children.
The search of several electronic databases will lead to source related published studies. The electronic databases include both English (PubMed, EMBASE, Web of Science, and the Cochrane Library) and Chinese (China National Knowledge Infrastructure, WanFang, and China Biomedical Database) databases. All studies published from inception to November 19, 2020 are searched. Study selection, extraction of data, and evaluation of the bias risk in included studies are carried out by two authors independently. The software, RevMan 5.3, is used to analyze the data.
This study provides evidence of substantial quality for the clinical therapeutic effects of methotrexate combined with other chemotherapeutic agents for treating osteosarcoma in children.
The results of this study provide conclusive evidence with regards to the clinical application of methotrexate combined with other chemotherapeutic agents for treating osteosarcoma in children.
Since this study will use published data, ethical approval is not required.
This protocol has been registered on INPLASY202110024.
骨肉瘤是一种原发性恶性骨肿瘤，常见于儿童。由于副作用和耐药性的形成，用化疗治疗骨肉瘤的临床疗效有限。目前，骨肉瘤化疗中使用多柔比星、顺铂、异环磷酰胺、表柔比星、甲氨蝶呤等混合药物。因此，本研究旨在探讨甲氨蝶呤联合其他化疗药物治疗儿童骨肉瘤的临床疗效。
通过对几个电子数据库进行搜索，查找与已发表的相关研究。电子数据库包括英文（PubMed、EMBASE、Web of Science 和 Cochrane Library）和中文（中国国家知识基础设施、万方和中国生物医学数据库）数据库。检索所有从建库开始至 2020 年 11 月 19 日发表的研究。由两位作者独立进行研究选择、数据提取和纳入研究偏倚风险评估。使用 RevMan 5.3 软件分析数据。
本研究为甲氨蝶呤联合其他化疗药物治疗儿童骨肉瘤的临床疗效提供了高质量的证据。
本研究结果为甲氨蝶呤联合其他化疗药物治疗儿童骨肉瘤的临床应用提供了确凿的证据。
由于本研究将使用已发表的数据，因此不需要伦理批准。
本方案已在 INPLASY202110024 上注册。
